Comparison 6. Triptans vs placebo in adolescents, sensitivity analysis.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.1 Study design	21	6794	Risk Ratio (M‐H, Random, 95% CI)	1.33 [1.19, 1.49]
6.1.1 Cross‐over	7	1127	Risk Ratio (M‐H, Random, 95% CI)	1.81 [1.44, 2.26]
6.1.2 Parallel	14	5667	Risk Ratio (M‐H, Random, 95% CI)	1.25 [1.12, 1.39]
6.2 Allocation concealment	21		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
6.2.1 Low	8	2365	Risk Ratio (M‐H, Random, 95% CI)	1.50 [1.19, 1.89]
6.2.2 Unclear	13	4429	Risk Ratio (M‐H, Random, 95% CI)	1.25 [1.12, 1.40]
6.3 Source of funding	21		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
6.3.1 Pharmaceutical	17	6332	Risk Ratio (M‐H, Random, 95% CI)	1.29 [1.16, 1.43]
6.3.2 Non‐pharmaceutical	2	104	Risk Ratio (M‐H, Random, 95% CI)	4.22 [1.50, 11.84]
6.3.3 Unclear	2	358	Risk Ratio (M‐H, Random, 95% CI)	1.76 [1.22, 2.54]
6.4 Reported in a journal	21		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
6.4.1 Journal report	15	5175	Risk Ratio (M‐H, Random, 95% CI)	1.34 [1.18, 1.52]
6.4.2 Registry or abstract only	6	1619	Risk Ratio (M‐H, Random, 95% CI)	1.26 [0.94, 1.71]
6.5 Sample size	21	6794	Risk Ratio (M‐H, Random, 95% CI)	1.33 [1.19, 1.49]
6.5.1 Sample size ≤ 50	2	104	Risk Ratio (M‐H, Random, 95% CI)	4.22 [1.50, 11.84]
6.5.2 Sample size > 50	19	6690	Risk Ratio (M‐H, Random, 95% CI)	1.31 [1.18, 1.46]